CN Patent

CN114621249B — 瑞卢戈利关键中间体的制备

Assigned to Jiangsu Huiju Pharmaceutical Co ltd · Expires 2024-01-26 · 2y expired

What this patent protects

本发明涉及瑞卢戈利关键中间体1‑(2,6‑二氟苄基)‑5‑((二甲基氨基)甲基)‑3‑(6‑甲氧基哒嗪‑3‑基)‑6‑(4‑硝基苯基)噻吩并[2,3‑d]嘧啶‑2,4(lH,3H)‑二酮的制备,具体为2‑((2,6‑二氟苄基)(乙氧基羰基)氨基)‑4‑((二甲氨基)甲基)‑5‑(4‑硝基苯基)噻吩‑3‑甲酸乙酯在碱/溶剂作用下和3‑氨基‑6‑甲氧基哒嗪反应。

USPTO Abstract

本发明涉及瑞卢戈利关键中间体1‑(2,6‑二氟苄基)‑5‑((二甲基氨基)甲基)‑3‑(6‑甲氧基哒嗪‑3‑基)‑6‑(4‑硝基苯基)噻吩并[2,3‑d]嘧啶‑2,4(lH,3H)‑二酮的制备,具体为2‑((2,6‑二氟苄基)(乙氧基羰基)氨基)‑4‑((二甲氨基)甲基)‑5‑(4‑硝基苯基)噻吩‑3‑甲酸乙酯在碱/溶剂作用下和3‑氨基‑6‑甲氧基哒嗪反应。

Drugs covered by this patent

Patent Metadata

Patent number
CN114621249B
Jurisdiction
CN
Classification
—
Expires
2024-01-26
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Huiju Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.